Anzeige
Mehr »
Login
Samstag, 25.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Achtung! Ist das die Krypto-Aktie des Jahres 2024 mit 700% Potential?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EW9Y | ISIN: US74006W2070 | Ticker-Symbol:
NASDAQ
24.05.24
21:59 Uhr
43,930 US-Dollar
+1,220
+2,86 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PRAXIS PRECISION MEDICINES INC Chart 1 Jahr
5-Tage-Chart
PRAXIS PRECISION MEDICINES INC 5-Tage-Chart

Aktuelle News zur PRAXIS PRECISION MEDICINES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.05.Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Investor Conferences1
16.05.Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know1
13.05.Praxis Precision Medicines Inc reports results for the quarter ended in March - Earnings Summary1
13.05.Praxis Precision Medicines GAAP EPS of -$2.84 misses by $0.75, revenue of $0.43M misses by $1.33M1
13.05.Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report1
13.05.Praxis Precision Medicines, Inc. - 8-K, Current Report1
13.05.Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results79Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong recruitment for the pivotal...
► Artikel lesen
10.05.Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 20241
03.05.Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)88BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
► Artikel lesen
12.04.Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting-
05.04.Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming April Conferences1
02.04.Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)63BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
► Artikel lesen
28.03.Praxis Precision Medicines dips after $200 million stock offering priced1
28.03.Praxis Precision Medicines Announces Pricing Of Underwritten Public Offering1
28.03.Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering3
27.03.Praxis Precision Medicines announces proposed public offering1
27.03.Praxis Precision Medicines, Inc. Announces Proposed Public Offering1
26.03.Praxis Precision Medicines Reports Positive Results From PRAX-628 Study2
26.03.Praxis Precision Medicines, Inc. - 8-K, Current Report1
26.03.Praxis Precision Medicines, Inc.: Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients86In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with...
► Artikel lesen
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1